After reviewing the available data the CHMP concluded that the balance of risks and benefits for Protopic is considered favourable.
Pärast olemasolevate andmete ülevaatamist järeldas inimtervishoius kasutatavate ravimite komitee, et Protopic’ i riski ja kasu suhe on soodus.